The burden alongside the benefit
Tolerability during weight loss
A desirable change can arrive with unwelcome effects. My judgement of the loss has to make room for both.
Digestive effects in SURMOUNT-1
In SURMOUNT-1, a tirzepatide trial in adults with obesity and without diabetes, the most common adverse effects were gastrointestinal, mostly mild to moderate, and concentrated during dose escalation.
Mild to moderate describes severity; it gives no reason to ignore the experience. Would the desired change feel worthwhile alongside the burden? That question matters to my judgement. That is a different question from the size of the weight result.
A dedicated semaglutide safety review in type 2 diabetes judged the overall risk-benefit profile favourable while describing gastrointestinal effects as the dominant adverse effects. That assessment and the burdens can occupy the same account.
Gallbladder and rare-event questions
The semaglutide safety review reported an increased risk of biliary disease, including cholelithiasis, or gallstones. It also described pancreatic and thyroid-cancer signals for which low incidence prevented definitive conclusions.
Uncertainty about those rare events sets the limit of my confidence. An unresolved rare-event question deserves continued attention even alongside a favourable overall assessment. Calling the question settled would add certainty the review does not supply.
Diabetic-retinopathy complications
In SUSTAIN-6, people with type 2 diabetes at high cardiovascular risk had higher rates of diabetic-retinopathy complications with semaglutide, with a hazard ratio of 1.76 and a 95% confidence interval of 1.11–2.78. This was a finding in the diabetes population studied.
The same trial reported a reduction in the composite of cardiovascular death, nonfatal heart attack or nonfatal stroke. My judgement needs both findings in view. The cardiovascular result earns respect; the eye complication finding earns a place beside it.
Lean-tissue loss
The SURMOUNT-1 body-composition substudy found that roughly 75% of lost weight was fat mass and roughly 25% lean mass in both the tirzepatide and placebo groups. The systematic body-composition review identifies the missing objective physical-function outcomes in its included trials.
This returns me to the site's central question. The total on the scale has contents, and my enthusiasm for loss depends partly on those contents. The physical-function discussion examines the relationship still to be established, while the weight results show the size of the total change.